Matrixyl (Palmitoyl Pentapeptide-4)

• The pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser, residues 212–216 of the type I procollagen C-terminal propeptide) was identified in 1993 as the minimum sequence that stimulated collagen and fibronectin production in mesenchymal cells [1]. Palmitoylated KTTKS (Pal-KTTKS, INCI palmitoyl pentapeptide-4; trade name Matrixyl) was developed to increase lipophilicity for formulation research [2].

Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.

• Matrikine-type signalling: KTTKS stimulated extracellular-matrix (collagen, fibronectin) production in fibroblast culture [1].
• Palmitoylation increased retention in skin layers compared with unmodified KTTKS in an in-vitro permeation study [2].

• Pal-KTTKS is used as a cosmetic ingredient. It is not a medicine and no medicinal clinical development was identified.

• No formal medicinal safety evaluation was identified; it is used as a cosmetic ingredient.

• In the permeation study, neither peptide crossed full-thickness skin into the receptor fluid [2].
• Much of the industry data is not peer-reviewed.

Store at −20 °C. Protect from light.

Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.

• Allow the sealed vial to reach room temperature before opening to limit condensation.
• Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
• Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.